In a significant advancement for women battling ovarian cancer, the U.S. Food and Drug Administration (FDA) has approved relacorilant, a first-in-class glucocorticoid receptor modulator, for leverage in combination with chemotherapy in patients whose disease has grow resistant to platinum-based treatments. This approval offers a new therapeutic option for a challenging-to-treat population, potentially improving outcomes where limited choices currently exist. The decision, announced on February 29, 2024, marks a turning point in how doctors approach platinum-resistant ovarian cancer, a disease that affects thousands of women annually.
Ovarian cancer is often diagnosed at a late stage, making treatment more difficult. While initial treatment with platinum-based chemotherapy is often effective, many patients eventually develop resistance, leading to disease progression. Relacorilant works differently than traditional chemotherapy, targeting the glucocorticoid receptor, which plays a role in cancer cell survival, and resistance. By modulating this receptor, relacorilant aims to re-sensitize cancer cells to chemotherapy, enhancing its effectiveness. This first glucocorticoid RA approved for ovarian cancer represents a novel approach to overcoming treatment resistance.
The approval is based on the results of the Phase 3 CORAL study , which demonstrated that relacorilant, when added to paclitaxel chemotherapy, significantly improved progression-free survival (PFS) in patients with platinum-resistant ovarian cancer. Specifically, patients treated with the combination experienced a median PFS of 5.6 months compared to 3.1 months for those receiving paclitaxel alone, representing a clinically meaningful benefit. Overall survival data are still maturing, but initial findings suggest a positive trend.
Understanding Platinum-Resistant Ovarian Cancer
Ovarian cancer is the fifth leading cause of cancer death among women in the United States, with an estimated 21,750 new cases diagnosed and around 13,880 deaths expected in 2024, according to the American Cancer Society . The majority of patients are diagnosed with advanced-stage disease. Initial treatment typically involves surgical removal of the tumor followed by platinum-based chemotherapy. However, a significant proportion of patients will experience a recurrence, and their cancer will become resistant to platinum-based drugs.
Platinum resistance can develop through various mechanisms, including DNA repair alterations and changes in drug transport. Once resistance occurs, treatment options become limited, often involving single-agent chemotherapy or participation in clinical trials. The approval of relacorilant addresses a critical unmet need in this patient population, offering a new avenue for treatment and potentially extending the time to disease progression.
How Relacorilant Works: A Novel Mechanism
Relacorilant, developed by Corcept Therapeutics, is a selective glucocorticoid receptor modulator. Unlike traditional glucocorticoids, which have broad effects throughout the body, relacorilant is designed to specifically block the glucocorticoid receptor in cancer cells. This blockage disrupts the signaling pathways that contribute to chemotherapy resistance, making the cancer cells more vulnerable to the effects of the drugs. The drug is administered orally, offering a convenient route of administration for patients.
Side Effects and Considerations
As with any cancer treatment, relacorilant is associated with potential side effects. Common side effects observed in the CORAL study included fatigue, nausea, diarrhea, and decreased appetite. More serious side effects, such as adrenal insufficiency, were also reported, though less frequently. Patients receiving relacorilant require careful monitoring for adrenal function and may need to receive corticosteroid replacement therapy. The FDA approval includes a warning about this risk.
The prescribing information for relacorilant emphasizes the importance of monitoring patients for signs and symptoms of adrenal insufficiency, including weakness, fatigue, and dizziness. Healthcare providers should also be aware of potential drug interactions, as relacorilant can affect the metabolism of other medications. It’s crucial for patients to discuss their complete medical history and all medications they are taking with their doctor before starting treatment.
What’s Next for Relacorilant and Ovarian Cancer Treatment?
With the FDA approval secured, relacorilant (marketed as ELUNIX) is now available for eligible patients with platinum-resistant ovarian cancer. Corcept Therapeutics is continuing to investigate relacorilant in other cancer types, including compact cell lung cancer and castration-resistant prostate cancer. Further research is also planned to explore the potential of relacorilant in combination with other chemotherapy regimens and immunotherapies.
The long-term impact of relacorilant on overall survival remains to be seen, and ongoing monitoring of patients in the CORAL study will provide valuable insights. The approval of this novel agent represents a significant step forward in the fight against ovarian cancer, offering hope to women who have exhausted other treatment options. For more information about relacorilant and ovarian cancer, patients are encouraged to consult with their healthcare provider and visit the National Cancer Institute’s website .
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one been affected by ovarian cancer? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might find it helpful.
Worth a look
